🔗 Share this article

This year's prestigious award in medical science was awarded for revolutionary findings that clarify how the immune system attacks dangerous infections while protecting the body's own cells.

A trio of renowned researchers—Japan's Shimon Sakaguchi and American scientists Mary Brunkow and Dr. Ramsdell—received this accolade.

Their research uncovered specialized "security guards" within the immune system that eliminate malfunctioning immune cells that could harming the body.

The findings are now paving the way for innovative therapies for autoimmune diseases and cancer.

These winners will divide a prize fund valued at 11m SEK.

Decisive Findings

"Their work has been decisive for comprehending how the immune system functions and the reason we don't all develop serious autoimmune diseases," commented the head of the Nobel Committee.

This team's studies address a core question: In what way does the defense system protect us from countless infections while keeping our own tissues unharmed?

The immune system employs white blood cells that scan for signs of infection, even pathogens and germs it has not met before.

Such cells utilize detectors—called recognition units—that are generated randomly in a vast number of combinations.

That gives the defense network the ability to combat a wide array of threats, but the unpredictability of the mechanism inevitably creates immune cells that can target the body.

Security Guards of the Immune System

Researchers previously knew that some of these harmful white blood cells were destroyed in the immune organ—where immune cells develop.

This year's Nobel Prize honors the discovery of T-reg cells—described as the immune system's "security guards"—which patrol the body to disarm any defenders that attack the body's own tissues.

We know that this mechanism fails in self-attack conditions such as type-1 diabetes, multiple sclerosis, and RA.

The Nobel panel stated, "The findings have established a novel area of investigation and spurred the development of innovative therapies, for example for tumors and autoimmune diseases."

Regarding cancer, regulatory T-cells prevent the body from attacking the tumor, so studies are focused on reducing their numbers.

In autoimmune diseases, trials are testing boosting T-reg cells so the body is no longer under attack. A comparable method could also be useful in reducing the chances of organ transplant rejection.

Innovative Studies

Professor Sakaguchi, of a Japanese institution, performed experiments on mice that had their thymus removed, causing self-attack conditions.

The researcher demonstrated that introducing immune cells from healthy mice could stop the disease—suggesting there was a system for blocking defenders from harming the body.

Dr. Brunkow, from the Institute for Systems Biology in Seattle, and Dr. Ramsdell, now at Sonoma Biotherapeutics in a California city, were investigating an genetic immune disorder in mice and people that led to the identification of a genetic factor vital for the way regulatory T-cells function.

"The groundbreaking work has uncovered how the body's defenses is kept in check by regulatory T cells, stopping it from mistakenly targeting the healthy cells," said a prominent biological science specialist.

"The research is a striking illustration of how fundamental physiological research can have broad consequences for human health."